Cytokinetics
CYTK
262 hedge funds and large institutions have $4.05B invested in Cytokinetics in 2022 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 103 increasing their positions, 74 reducing their positions, and 18 closing their positions.
470% more call options, than puts
Call options by funds: $33.9M | Put options by funds: $5.95M
150% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 18
50% more funds holding in top 10
Funds holding in top 10: 8 → 12 (+4)
39% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 74
19% more capital invested
Capital invested by funds: $3.4B → $4.05B (+$648M)
11.03% more ownership
Funds ownership: 112.59% → 123.61% (+11%)
9% more funds holding
Funds holding: 240 → 262 (+22)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$176M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$102M |
| 3 |
Lazard Asset Management
New York
|
+$68.3M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$53.2M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$29.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$64.5M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$36.3M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$27.6M |
| 4 |
HM
HealthCor Management
New York
|
-$26.1M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$14.2M |
CYTK Hedge Fund Activity: Q2 2022 in Review
262 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q2 2022, worth a combined $4.05B — up 19% from $3.4B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new CYTK positions and 18 closed out — a net gain of 27 holders — while 103 added to existing stakes and 74 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $176M. The largest seller was Point72 Asset Management, cutting an estimated $64.5M.
- 262 institutional investors held Cytokinetics (CYTK) as of Q2 2022, up from 240 in Q1 2022.
- Funds reported $4.05B of Cytokinetics stock for Q2 2022, up 19% quarter-over-quarter.
- 45 funds opened new Cytokinetics positions in Q2 2022 and 18 closed out, a net change of +27 holders.
- The largest Cytokinetics buyer in Q2 2022 was Citadel Advisors, an estimated $176M added.
- The largest Cytokinetics seller in Q2 2022 was Point72 Asset Management, an estimated $64.5M sold.
Based on aggregated 13F filings for Q2 2022.